1,500
Participants
Start Date
January 6, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
June 30, 2025
TruGenome Cardiovascular Disease test
The TruGenome Cardiovascular Disease (CVD) test which consists of an in-silico 200 gene cardiovascular disease panel, a further 4 genes with cardiovascular disease risk alleles, 10 pharmacogenomic genes, 35 non-cardiovascular ACMG secondary finding genes and a polygenic risk score (PRS) for coronary artery disease (CAD) will be utilized in this study.
Henry Ford Health System, Detroit
Lead Sponsor
Henry Ford Health System
OTHER
Illumina, Inc.
INDUSTRY